Lexicon Pharmaceuticals (LXRX) Position Trimmed by BlackRock Inc.

BlackRock Inc. trimmed its position in shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) by 9.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,355,908 shares of the biopharmaceutical company’s stock after selling 475,745 shares during the period. BlackRock Inc. owned 4.13% of Lexicon Pharmaceuticals worth $43,038,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of LXRX. Quantitative Systematic Strategies LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $117,000. Aperio Group LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $127,000. Cubist Systematic Strategies LLC bought a new position in Lexicon Pharmaceuticals during the third quarter worth $149,000. Teacher Retirement System of Texas bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $161,000. Finally, First Trust Advisors LP bought a new position in Lexicon Pharmaceuticals during the third quarter worth $360,000.

How to Become a New Pot Stock Millionaire

LXRX has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. BidaskClub raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Needham & Company LLC cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, JPMorgan Chase cut shares of Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and reduced their price objective for the stock from $15.00 to $10.00 in a research report on Wednesday, February 14th. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $24.00.

LXRX stock opened at $8.57 on Monday. The firm has a market cap of $904.92, a price-to-earnings ratio of -6.75 and a beta of 0.40. Lexicon Pharmaceuticals has a one year low of $7.80 and a one year high of $18.00. The company has a debt-to-equity ratio of 4.44, a current ratio of 2.59 and a quick ratio of 2.58.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.12. The company had revenue of $33.05 million during the quarter, compared to analysts’ expectations of $29.84 million. Lexicon Pharmaceuticals had a negative net margin of 142.86% and a negative return on equity of 143.31%. Lexicon Pharmaceuticals’s quarterly revenue was up 43.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.31) earnings per share. sell-side analysts anticipate that Lexicon Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Lexicon Pharmaceuticals (LXRX) Position Trimmed by BlackRock Inc.” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3342517/lexicon-pharmaceuticals-lxrx-position-trimmed-by-blackrock-inc.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Energy Fuels  Director Dennis Lyle Higgs Sells 10,000 Shares of Stock
Energy Fuels Director Dennis Lyle Higgs Sells 10,000 Shares of Stock
TSE Technischer Service und Equipment – Hasenschwandtner Peter  Insider Nathan Mekuz Purchases 40,000 Shares
TSE Technischer Service und Equipment – Hasenschwandtner Peter Insider Nathan Mekuz Purchases 40,000 Shares
Commerce Bancshares  VP Daniel D. Callahan Sells 1,057 Shares
Commerce Bancshares VP Daniel D. Callahan Sells 1,057 Shares
Tupperware Brands  VP Lillian D. Garcia Acquires 2,320 Shares
Tupperware Brands VP Lillian D. Garcia Acquires 2,320 Shares
CompuCoin  Price Up 17.3% This Week
CompuCoin Price Up 17.3% This Week
U.CASH Price Tops $0.0037
U.CASH Price Tops $0.0037


Leave a Reply

© 2006-2018 Ticker Report. Google+.